 Drug-Related Side Effects and Adverse Reactions
"Drug-Related Side Effects and Adverse Reactions" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.
| Descriptor ID |
D064420
|
| MeSH Number(s) |
C25.100
|
| Concept/Terms |
Drug-Related Side Effects and Adverse Reactions- Drug-Related Side Effects and Adverse Reactions
- Drug Related Side Effects and Adverse Reactions
- Side Effects of Drugs
- Drug Side Effects
- Drug Side Effect
- Effects, Drug Side
- Side Effect, Drug
- Side Effects, Drug
- Adverse Drug Reaction
- Adverse Drug Reactions
- Drug Reaction, Adverse
- Drug Reactions, Adverse
- Reactions, Adverse Drug
- Adverse Drug Event
- Adverse Drug Events
- Drug Event, Adverse
- Drug Events, Adverse
Drug Toxicity- Drug Toxicity
- Toxicity, Drug
- Drug Toxicities
- Toxicities, Drug
|
Below are MeSH descriptors whose meaning is more general than "Drug-Related Side Effects and Adverse Reactions".
Below are MeSH descriptors whose meaning is more specific than "Drug-Related Side Effects and Adverse Reactions".
This graph shows the total number of publications written about "Drug-Related Side Effects and Adverse Reactions" by people in this website by year, and whether "Drug-Related Side Effects and Adverse Reactions" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 0 | 2 | 2 | | 2001 | 3 | 0 | 3 | | 2002 | 1 | 0 | 1 | | 2004 | 2 | 1 | 3 | | 2005 | 1 | 0 | 1 | | 2006 | 3 | 4 | 7 | | 2007 | 1 | 6 | 7 | | 2008 | 0 | 5 | 5 | | 2009 | 0 | 4 | 4 | | 2010 | 1 | 1 | 2 | | 2011 | 5 | 3 | 8 | | 2012 | 5 | 5 | 10 | | 2013 | 8 | 9 | 17 | | 2014 | 5 | 4 | 9 | | 2015 | 9 | 4 | 13 | | 2016 | 5 | 5 | 10 | | 2017 | 7 | 9 | 16 | | 2018 | 14 | 4 | 18 | | 2019 | 6 | 5 | 11 | | 2020 | 12 | 2 | 14 | | 2021 | 6 | 3 | 9 | | 2022 | 14 | 1 | 15 | | 2023 | 11 | 0 | 11 |
To return to the timeline, click here.
Below are the most recent publications written about "Drug-Related Side Effects and Adverse Reactions" by people in Profiles.
-
Green HH, Ray L, Buchanan J, Matsler N. Urinary retention and mydriasis secondary to topical glycopyrronium for axillary hyperhidrosis. Am J Health Syst Pharm. 2023 09 07; 80(18):1234-1237.
-
Davis SR, Pinkerton J, Santoro N, Simoncini T. Menopause-Biology, consequences, supportive care, and therapeutic options. Cell. 2023 09 14; 186(19):4038-4058.
-
Dart RC, Mullins ME, Matoushek T, Ruha AM, Burns MM, Simone K, Beuhler MC, Heard KJ, Mazer-Amirshahi M, Stork CM, Varney SM, Funk AR, Cantrell LF, Cole JB, Banner W, Stolbach AI, Hendrickson RG, Lucyk SN, Sivilotti MLA, Su MK, Nelson LS, Rumack BH. Management of Acetaminophen Poisoning in the US and Canada: A Consensus Statement. JAMA Netw Open. 2023 08 01; 6(8):e2327739.
-
King-Kallimanis BL, Calvert M, Cella D, Cocks K, Coens C, Fairclough D, Howie L, Jonsson P, Mahendraratnam N, Maues J, Sarac S, Shaw J, Stigger N, Trask P, Wieseler B. Perspectives on Patient-Reported Outcome Data After Treatment Discontinuation in Cancer Clinical Trials. Value Health. 2023 10; 26(10):1543-1548.
-
Sadowski C, Belknap R, Holland DP, Moro RN, Chen MP, Wright A, Millet JP, Cayl? JA, Scott NA, Borisov A, Gandhi NR. Symptoms and Systemic Drug Reactions in Persons Receiving Weekly Rifapentine Plus Isoniazid (3HP) Treatment for Latent Tuberculosis Infection. Clin Infect Dis. 2023 Jun 16; 76(12):2090-2097.
-
Bathgate CJ, Muther E, Georgiopoulos AM, Smith B, Tillman L, Graziano S, Verkleij M, Lomas P, Quittner A. Positive and negative impacts of elexacaftor/tezacaftor/ivacaftor: Healthcare providers' observations across US centers. Pediatr Pulmonol. 2023 09; 58(9):2469-2477.
-
Boussetta-Charfi O, D'Andon CF, Nguyen H, Rumack BH, Launay M. Failure of Risk Assessment After Paracetamol Overdose-A Short Communication. Ther Drug Monit. 2023 04 01; 45(2):273-276.
-
Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, Thibert R. Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE). Epilepsy Behav. 2023 05; 142:109173.
-
Albrecht JM, Cooper BR, Waller JD, Presley CL, Pulsipher KJ, Rundle CW, Dellavalle RP. Nirmatrelvir-ritonivir, COVID-19, and possible adverse cutaneous reactions. Dermatol Online J. 2023 Feb 15; 29(1).
-
Alosaimy S, Lagnf AM, Hobbs ALV, Mubarez M, Kufel WD, Morrisette T, Polisetty RS, Li D, Veve MP, Simon SP, Truong J, Finch N, Venugopalan V, Rico M, Amaya L, Yost C, Cubillos A, Chandler E, Patch M, Smith IMK, Biagi M, Wrin J, Moore WJ, Molina KC, Rebold N, Holger D, Kunz Coyne AJ, Jorgensen SCJ, Witucki P, Tran NN, Davis SL, Sakoulas G, Rybak MJ. Nephrotoxicity of Vancomycin in Combination With Beta-Lactam Agents: Ceftolozane-Tazobactam vs Piperacillin-Tazobactam. Clin Infect Dis. 2023 02 08; 76(3):e1444-e1455.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|